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Oral Presentations 13was cyclosporine with four doses of methotrexate in 97 patients and
other treatments in 5. Overall survival at 5 years was 61% and re-
lapse-free survival was 56%. The incidence of acute GvHD grades
II-IV was 62% in patients with an LC30 of\0.2  109/L, 33% if
the LC30 was 0.2–1.0  109/L and 25% in patients with an LC30
.1.0  109/L (p 5 0.008). Transplant related mortality (TRM)
was 34% in patients with an LC30\0.2  109 versus 19% (LC30
of 0.2–1.0  109) and 0% (LC30 .1.0  109) (p\0.001). Survival
was significantly higher in 17 patients with an LC30 .1.0  109/L,
compared to 67 patients with an LC30 0.2–1.0  109/L, and 18 pa-
tients with \0.2  109/L (91% vs. 60%, vs. 36% p 5 0.02 and
0.001 respectively). When analyzed as a continuous variable in mul-
tivariate analysis, a higher LC30 was associated with a lower inci-
dence of acute GvHD grades II-IV, improved survival, less relapse
and higher relapse-free survival. Plasma levels of cytokines were mea-
sured in 15 subjects between day 12–32 post-transplant (total 21 sam-
ples). Six patients had a low (\0.2109/L) and 9 patients a high (.1.0
 109/L) LC30. Plasma IL-15 was lower in patients with high LC30
(median 32 pg/ml vs. 56.5 pg/ml, p\0.05 log rank sum). These re-
sults indicate that the LC30 is a robust prognostic factor for trans-
plant outcome in matched unrelated as well as matched related
SCT for myeloid malignancies receiving either BM or PBSC with
or without irradiation conditioning. Further research to identify
the transplant conditions leading to prompt lymphocyte recovery
might lead to global improvements in SCT outcome in unrelated
SCT.28
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NKT cells, which are CD1d reactive, are thought to play an im-
munoregulatory role in suppressing dysfunctional immune reac-
tions, including graft-versus-host disease (GVHD). However, we
do not know if non-manipulated donor-type NKT can suppress
GVHD or how NKT proliferate and migrate following hemato-
poetic cell transplantation (HCT). We transferred 5.5  105 highly
purified (.95%) NKT (DX51TCR1CD41) from luciferase posi-
tive (luc1) C57BL/6 (H-2b) mice into lethally irradiated Balb/c (H-
2d) recipients with 5 106 T-cell depleted bone marrow (TCD-BM)
from wild-type (WT) C57BL/6 mice, and monitored them by biolu-
minescence imaging (BLI). By day 4 after transfer, a signal was ob-
served in spleen and lymph node (LN) sites, and between days 7
and 10, NKT had also migrated to skin. Total photons emitted
peaked around day 25 after transplantation, followed by a steady de-
cline. To assess the impact of donor-type NKT on GVHD induction
by Tcon, we co-transferred various doses of highly pure WT NKT
at day 0 with 5  106 TCD-BM, followed by 5  105 luc1Tcon at
day 2. We have found that adoptive transfer of as few as 2.5  10 4
NKT can significantly improve survival of mice receiving 5  105
Tcon. Survival with Tcon only was 20% and for Tcon with NKT
was 74%; p 5 0.0023. To determine how NKT reduce GVHD,
we examined intracellular levels of various cytokines in Tcon with
or without 2.5  104 NKT, following HCT. At 8 days after HCT,
mice receiving NKT had fewer TNFa-positive cells from LNs
(CD4: 45% to 27%; CD8 36% to 24%); by day 11, however,
TNFa levels between groups were equivalent. IFN-g levels, which
were high in both NKT treated and untreated groups at day 8
(85%-95%), decreased significantly in NKT treated mice by day
11 (CD4: 40%; CD8: 43%), but were abundant in Tcon only mice
(CD4: 78%; CD8: 80%) (p 5 .0001). NKT from both IL-4 -/-
and IFN-g -/- mice were less effective at suppressing GVHD than
WT NKT, implicating these cytokines in the suppressive mecha-
nism. Finally, we found that NKT do not have a major impact on
the graft-versus-tumor effect of Tcon against a luc1BCL-1 tumor.
These studies indicate that NKT persist in vivo upon adoptive trans-
fer and suppress GVHD, even at extremely low cell numbers, which
is important given the relative paucity of this cell population. The
mechanisms of GVHD suppression appear to be distinct to those
of CD41CD251FoxP31 Treg and involve the production of
IL-4 and IFN-g by NKT and a decrease in Tcon which produce
pro-inflamatory cytokines.29
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Carcinoembryonic antigen associated cell adhesion molecule 1
(Ceacam1) is a type I transmembrane glycoprotein that regulates
numerous processes including bacterial colonization of the gastro-
intestinal lumen and leukocyte function. Ceacam1 is expressed on
gut epithelium and activated T cells, particularly in the intestines.
We found that T cells from Ceacam1-/- mice had elevated phos-
phorylation of STAT3. Upon stimulation with anti-CD31CD28,
IL-2, IL-4, IL-6, or IL-12 in vitro, Ceacam1-/- T cells showed hy-
perphosphorylation of corresponding canonical STAT proteins,
indicating that Ceacam1 can regulate the sensitivity of T cells to cy-
tokines and TCR stimulation. Ceacam1-/- T cells also had defec-
tive anergy induction as measured by IL-2 secretion. This was
associated with decreased cleaved caspase 3 (but not decreased ap-
optosis) and hypophosphorylation of STAT1 upon IFNg treat-
ment. We assessed Ceacam1 regulation of T cells in vivo during
GVHD. Ceacam1-/- T cells caused increased mortality and large
intestinal GVHD, had more profound activation (CD25,
CD62L) and expression of integrin a4b7 and demonstrated selec-
tive infiltration of the intestines. By contrast, Ceacam1-overex-
pressing T cells caused significantly less GVHD mortality and
damage to all target organs, which correlated with decreased prolif-
eration and organ infiltration. We also studied Ceacam1 in recipi-
ents of allogeneic bone marrow transplantation (allo-BMT), and
found that compared to wildtype (WT) recipients, Ceacam1-/- re-
cipients with GVHD showed accelerated mortality and increased
damage to the large intestines and thymus. Donor alloactivated
CD4 T cells in Ceacam1-/- allo-BMT recipients had increased ac-
tivation (CD25), and trafficked preferentially to the mesenteric
lymph nodes, small and large bowel, but had decreased accumula-
tion in the liver and peripheral lymph nodes (PLN). Finally, Cea-
cam1-/- mice were more sensitive to radiation injury as
demonstrated by accelerated kinetics of mortality and decreased
numbers of surviving or regenerating small intestinal crypts. We
conclude that Ceacam1 is an important regulator of alloreactivity
during GVHD through its effects on T cell (allo)activation, prolif-
eration, trafficking, cytokine sensitivity, and anergy. Moreover,
Ceacam1 expression on gut epithelium regulates sensitivity to
radiation injury, T cell alloreactivity, and intestinal GVHD.30
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There are no plasma biomarkers specific to any of the three target
organs of acute graft versus host disease (GVHD): skin, GI tract
and liver. We sought to identify a biomarker for skin GVHD in
an initial discovery step using an intact proteomic analysis system.
We compared plasma pooled from ten patients with skin GVHD
only (sGVHD) to ten patients without GVHD (–GVHD) to ten pa-
tients with GI tract GVHD only (giGVHD). Of four candidate
proteins that were both significantly elevated only in the plasma
of sGVHD and that could be measured by ELISA, we selected ela-
fin, an epidermal proteinase inhibitor that is induced by TNF-a and
found in inflamed epidermis. We measured levels of elafin
